1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 TBI Therapeutics: Introduction 6
2.1 Disease Overview 6
2.2 Epidemiology 9
2.3 Etiology 9
2.4 Signs and Symptoms 10
2.5 Diagnosis 10
2.6 Treatment and management Pattern 12
2.7 GlobalData Pipeline Report Guidance 14
3 TBI Therapeutics: Market Characterization 15
3.1 Overview 15
3.2 TBI Therapeutics Market Size (2005–2010) – Global 15
3.3 TBI Therapeutics Market Forecast (2010–2017) – Global 16
3.4 TBI Therapeutics Market Size (2005–2010) – The US 17
3.5 TBI Therapeutics Market Forecast (2010–2017) – The US 18
3.6 TBI Therapeutics Market Size (2005–2010) – France 19
3.7 TBI Therapeutics Market Forecast (2010–2017) – France 20
3.8 TBI Therapeutics Market Size (2005–2010) – Germany 21
3.9 TBI Therapeutics Market Forecast (2010-2017) – Germany 22
3.10 TBI Therapeutics Market Size (2005–2010) – Italy 23
3.11 TBI Therapeutics Market Forecast (2010–2017) – Italy 24
3.12 TBI Therapeutics Market Size (2005–2010) – Spain 25
3.13 TBI Therapeutics Market Forecast (2010–2017) – Spain 26
3.14 TBI Therapeutics Market Size (2005–2010) – The UK 27
3.15 TBI Therapeutics Market Forecast (2010–2017) – The UK 28
3.16 TBI Therapeutics Market Size (2005–2010) – Japan 29
3.17 TBI Therapeutics Market Forecast (2010–2017) – Japan 30
3.18 Drivers and Barriers for TBI Therapeutics Market 31
3.18.1 Drivers for the TBI Therapeutics Market 31
3.18.2 Barriers for the TBI Therapeutics Market 31
3.19 Opportunity and Unmet Need Analysis 32
3.19.1 Opportunity and Unmet Need in the TBI Market, 2010 32
3.20 Key Takeaway 32
4 TBI Therapeutics: Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profile for the Major Marketed Products in the TBI Therapeutics 34
4.3.1 NovoSeven 34
4.3.2 Mannitol 35
4.4 Key Takeaway 35
5 TBI Therapeutics: Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 TBI Therapeutics Pipeline – Pipeline by Phases of Development 36
5.3.1 TBI Therapeutics – Phase III Pipeline 37
5.3.2 TBI Therapeutics –Phase II Pipeline 37
5.3.3 TBI Therapeutics –Phase I Pipeline 38
5.3.4 TBI Therapeutics – Preclinical Phase 38
5.3.5 TBI Therapeutics – Discovery Pipeline 38
5.4 Technology Trends Analytic Framework 39
5.5 TBI Therapeutics – Clinical Pipeline by Mechanism of Action 41
5.6 TBI Therapeutics – Promising Drugs under Clinical Development 42
5.7 Molecule Profiling for Promising Drugs under Clinical development 42
5.7.1 BHR-100 42
5.7.2 NHOO1 43
5.8 Key Takeaway 43
6 TBI Therapeutics: Clinical Trials Mapping 44
6.1 Clinical Trials by Region/ Country 44
6.2 Clinical Trials by Phase 45
6.3 Clinical Trials by Trial Status 46
6.4 Top 10 companies participating in Therapeutics Clinical Trials 47
6.5 Prominent Sponsors 48
7 TBI Therapeutics: Strategic Assessment 50
7.1 Key Events Impacting the Future Market 50
7.2 Implications for Future Market Competition 51
8 TBI Therapeutics: Future Players 52
8.1 Introduction 52
8.2 Company Profiles 52
8.2.1 BHR Pharma, LLC 52
8.2.2 Vasopharm GmbH 53
8.2.3 NeuroHealing Pharmaceuticals Inc. 54
9 TBI Therapeutics: Licensing and Partnership Deals 55
10 TBI Therapeutics: Appendix 56
10.1 Market Definitions 56
10.2 Abbreviations 56
10.3 Research Methodology 57
10.3.1 Coverage 57
10.3.2 Secondary Research 57
10.3.3 Forecasting 58
10.3.4 Primary Research 61
10.3.5 Expert Panel Validation 61
10.4 Contact Us 61
10.5 Disclaimer 61
10.6 Bibliography 62